
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics has demonstrated a commitment to enhancing patient safety and simplifying clinical procedures through its strategic shift to standard FC lymphodepletion in the ALPHA3 trial, which preserves the trial's statistical integrity. The company's pipeline reflects a strong focus on off-the-shelf T-cell therapies intended for diverse cancer profiles, indicating robust scalability and potential for broad patient eligibility. Additionally, the significant participation in minimal residual disease (MRD) screening, with over 90% patient consent rates, underscores the strong engagement in the enrollment process, supporting Allogene's trajectory towards successful clinical outcomes and commercial viability.
Bears say
Allogene Therapeutics Inc faces substantial risks regarding the approval of its clinical assets, with potential delays likely to adversely affect its stock performance. The inherent uncertainties associated with clinical trials may lead to failures in demonstrating adequate efficacy or safety, which could further jeopardize the company’s prospects. Additionally, the regulatory landscape introduces further commercial risks that could impede the progression and financial viability of Allogene's therapeutic offerings.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares